{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,31]],"date-time":"2026-01-31T08:42:17Z","timestamp":1769848937788,"version":"3.49.0"},"reference-count":15,"publisher":"Elsevier BV","issue":"5","license":[{"start":{"date-parts":[[2018,5,1]],"date-time":"2018-05-01T00:00:00Z","timestamp":1525132800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2020,1,7]],"date-time":"2020-01-07T00:00:00Z","timestamp":1578355200000},"content-version":"vor","delay-in-days":616,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"}],"funder":[{"DOI":"10.13039\/501100005010","name":"AIRC","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100005010","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100005010","name":"Associazione Italiana per la Ricerca sul Cancro","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100005010","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Annals of Oncology"],"published-print":{"date-parts":[[2018,5]]},"DOI":"10.1093\/annonc\/mdy062","type":"journal-article","created":{"date-parts":[[2018,2,15]],"date-time":"2018-02-15T20:10:34Z","timestamp":1518725434000},"page":"1189-1194","source":"Crossref","is-referenced-by-count":9,"title":["Quality-of-life analysis of the MITO-8, MaNGO, BGOG-Ov1, AGO-Ovar2.16, ENGOT-Ov1, GCIG study comparing platinum-based versus non-platinum-based chemotherapy in patients with partially platinum-sensitive recurrent ovarian cancer"],"prefix":"10.1016","volume":"29","author":[{"given":"M.C.","family":"Piccirillo","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"G.","family":"Scambia","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"A.","family":"Bologna","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"S.","family":"Signoriello","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"I.","family":"Vergote","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"K.","family":"Baumann","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"D.","family":"Lorusso","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"V.","family":"Murgia","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"R.","family":"Sorio","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"G.","family":"Ferrandina","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"C.","family":"Sacco","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"G.","family":"Cormio","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"E.","family":"Breda","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"S.","family":"Cinieri","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"D.","family":"Natale","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"G.","family":"Mangili","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"C.","family":"Pisano","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"S.C.","family":"Cecere","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"M.","family":"Di Napoli","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"V.","family":"Salutari","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"F.","family":"Raspagliesi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"L.","family":"Arenare","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"A.","family":"Bergamini","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"J.","family":"Bryce","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"G.","family":"Daniele","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"C.","family":"Gallo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"S.","family":"Pignata","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9738-0526","authenticated-orcid":false,"given":"F.","family":"Perrone","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"2","key":"10.1093\/annonc\/mdy062_bb0010","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1016\/0090-8258(90)90174-J","article-title":"Treatment of relapsed carcinoma of the ovary with cisplatin or carboplatin following initial treatment with these compounds","volume":"36","author":"Gore","year":"1990","journal-title":"Gynecol Oncol"},{"issue":"3","key":"10.1093\/annonc\/mdy062_bb0015","doi-asserted-by":"crossref","first-page":"389","DOI":"10.1200\/JCO.1991.9.3.389","article-title":"Second-line platinum therapy in patients with ovarian cancer previously treated with cisplatin","volume":"9","author":"Markman","year":"1991","journal-title":"J Clin Oncol"},{"issue":"2","key":"10.1093\/annonc\/mdy062_bb0020","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1634\/theoncologist.4-2-87","article-title":"Extending the platinum-free interval in recurrent ovarian cancer: the role of topotecan in second-line chemotherapy","volume":"4","author":"Bookman","year":"1999","journal-title":"Oncologist"},{"issue":"29","key":"10.1093\/annonc\/mdy062_bb0025","doi-asserted-by":"crossref","first-page":"3347","DOI":"10.1200\/JCO.2017.73.4293","article-title":"Randomized controlled trial testing the efficacy of platinum-free interval prolongation in advanced ovarian cancer: the MITO-8, MaNGO, BGOG-Ov1, AGO-Ovar2.16, ENGOT-Ov1, GCIG Study","volume":"35","author":"Pignata","year":"2017","journal-title":"JCO"},{"issue":"3","key":"10.1093\/annonc\/mdy062_bb0030","doi-asserted-by":"crossref","first-page":"476","DOI":"10.1111\/IGC.0b013e3181d3caa8","article-title":"European Network of Gynaecological Oncological Trial Groups' requirements for trials between academic groups and pharmaceutical companies","volume":"20","author":"Vergote","year":"2010","journal-title":"Int J Gynecol Cancer"},{"issue":"5","key":"10.1093\/annonc\/mdy062_bb0035","doi-asserted-by":"crossref","first-page":"365","DOI":"10.1093\/jnci\/85.5.365","article-title":"The European Organization for Research and Treatment of Cancer QLQ-C30: a quality-of-life instrument for use in international clinical trials in oncology","volume":"85","author":"Aaronson","year":"1993","journal-title":"J Natl Cancer Inst"},{"issue":"10","key":"10.1093\/annonc\/mdy062_bb0040","doi-asserted-by":"crossref","first-page":"1402","DOI":"10.1016\/S0959-8049(03)00307-1","article-title":"An international field study of the reliability and validity of a disease-specific questionnaire module (the QLQ-OV28) in assessing the quality of life of patients with ovarian cancer","volume":"39","author":"Greimel","year":"2003","journal-title":"Eur J Cancer"},{"issue":"5","key":"10.1093\/annonc\/mdy062_bb0045","doi-asserted-by":"crossref","first-page":"353","DOI":"10.1007\/BF00451727","article-title":"Psychometric properties and responsiveness of the EORTC quality of Life Questionnaire (QLQ-C30) in patients with breast, ovarian and lung cancer","volume":"3","author":"Osoba","year":"1994","journal-title":"Qual Life Res"},{"issue":"2","key":"10.1093\/annonc\/mdy062_bb0050","doi-asserted-by":"crossref","first-page":"280","DOI":"10.1016\/j.ejca.2004.10.017","article-title":"Analysis and interpretation of health-related quality-of-life data from clinical trials: basic approach of The National Cancer Institute of Canada Clinical Trials Group","volume":"41","author":"Osoba","year":"2005","journal-title":"Eur J Cancer"},{"issue":"1","key":"10.1093\/annonc\/mdy062_bb0055","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1200\/JCO.1998.16.1.139","article-title":"Interpreting the significance of changes in health-related quality-of-life scores","volume":"16","author":"Osoba","year":"1998","journal-title":"J Clin Oncol"},{"issue":"6","key":"10.1093\/annonc\/mdy062_bb0060","doi-asserted-by":"crossref","first-page":"487","DOI":"10.1093\/jnci\/djh081","article-title":"Re: new guidelines to evaluate the response to treatment in solid tumors (ovarian cancer)","volume":"96","author":"Rustin","year":"2004","journal-title":"J Natl Cancer Inst"},{"issue":"3","key":"10.1093\/annonc\/mdy062_bb0065","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1093\/jnci\/92.3.205","article-title":"New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada","volume":"92","author":"Therasse","year":"2000","journal-title":"J Natl Cancer Inst"},{"issue":"1","key":"10.1093\/annonc\/mdy062_bb0070","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1016\/j.ygyno.2012.06.034","article-title":"Patient-reported outcomes in relapsed ovarian cancer: results from a randomized phase III study of trabectedin with pegylated liposomal doxorubicin (PLD) versus PLD alone","volume":"127","author":"Krasner","year":"2012","journal-title":"Gynecol Oncol"},{"issue":"6","key":"10.1093\/annonc\/mdy062_bb0075","doi-asserted-by":"crossref","first-page":"1006","DOI":"10.1093\/annonc\/mdw147","article-title":"Health-related quality of life in women with recurrent ovarian cancer receiving paclitaxel plus trebananib or placebo (TRINOVA-1)","volume":"27","author":"Fujiwara","year":"2016","journal-title":"Ann Oncol"},{"key":"10.1093\/annonc\/mdy062_bb0080","doi-asserted-by":"crossref","first-page":"727","DOI":"10.1093\/annonc\/mdw663","article-title":"Fifth Ovarian Cancer Consensus Conference of the Gynecologic Cancer InterGroup: recurrent disease","volume":"28","author":"Wilson","year":"2017","journal-title":"Ann Oncol"}],"container-title":["Annals of Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0923753419345351?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0923753419345351?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/academic.oup.com\/annonc\/article-pdf\/29\/5\/1189\/24831750\/mdy062.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,6,26]],"date-time":"2021-06-26T08:39:43Z","timestamp":1624696783000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0923753419345351"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,5]]},"references-count":15,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2018,5]]}},"alternative-id":["S0923753419345351"],"URL":"https:\/\/doi.org\/10.1093\/annonc\/mdy062","relation":{},"ISSN":["0923-7534"],"issn-type":[{"value":"0923-7534","type":"print"}],"subject":[],"published":{"date-parts":[[2018,5]]}}}